The meeting gave investigators across China a common understanding and a firmer basis for standardized multi-center execution, while the expert discussion charted a course for clinical development and international expansion. ImmuneCare looks forward to working with investigators in China to bring this differentiated ActRIIA molecule to patients with pulmonary arterial hypertension as early as possible.